Teva Pharmaceutical Industries LimitedTEVANYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+102.3%
5Y CAGR+1.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+102.3%/yr
Quarterly compound
5Y CAGR
+1.2%/yr
Recent acceleration
Percentile
P95
Near historical high
vs 5Y Ago
1.1x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 15.11% |
| Q3 2025 | 1.46% |
| Q2 2025 | 4.35% |
| Q1 2025 | -3.47% |
| Q4 2024 | 3.03% |
| Q3 2024 | -1.60% |
| Q2 2024 | 5.98% |
| Q1 2024 | -1.77% |
| Q4 2023 | 6.87% |
| Q3 2023 | -7.25% |
| Q2 2023 | 8.08% |
| Q1 2023 | 0.60% |
| Q4 2022 | 1.82% |
| Q3 2022 | -9.37% |
| Q2 2022 | 3.07% |
| Q1 2022 | -3.08% |
| Q4 2021 | 2.25% |
| Q3 2021 | 3.62% |
| Q2 2021 | -2.06% |
| Q1 2021 | -13.37% |
| Q4 2020 | 14.25% |
| Q3 2020 | 2.67% |
| Q2 2020 | -6.11% |
| Q1 2020 | -10.54% |
| Q4 2019 | 16.48% |
| Q3 2019 | -8.52% |
| Q2 2019 | 2.34% |
| Q1 2019 | -17.62% |
| Q4 2018 | 8.46% |
| Q3 2018 | 2.53% |
| Q2 2018 | -6.73% |
| Q1 2018 | -18.94% |
| Q4 2017 | 14.03% |
| Q3 2017 | -3.41% |
| Q2 2017 | 2.07% |
| Q1 2017 | -16.18% |
| Q4 2016 | 15.20% |
| Q3 2016 | -1.03% |
| Q2 2016 | 10.50% |
| Q1 2016 | -5.30% |